• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口服促性腺激素释放激素拮抗剂艾拉戈利的临床开发

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix.

作者信息

Chwalisz Kristof

机构信息

Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, Grand Rapids, Michigan.

出版信息

F S Rep. 2023 Feb 4;4(2 Suppl):65-72. doi: 10.1016/j.xfre.2023.02.002. eCollection 2023 Jun.

DOI:10.1016/j.xfre.2023.02.002
PMID:37223767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10201304/
Abstract

Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval.

摘要

艾拉戈利是首个进入临床开发并获得监管批准的口服促性腺激素释放激素拮抗剂，用于联合激素补充疗法治疗患有子宫内膜异位症和与子宫肌瘤相关的月经过多的女性。本综述旨在总结促成其获得监管批准的关键临床研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/44d14ad3a4e0/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/19c10e335255/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/519f34354c74/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/9580e4eb8e72/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/abaf9a3a3139/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/a04d1bb46ef7/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/44d14ad3a4e0/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/19c10e335255/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/519f34354c74/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/9580e4eb8e72/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/abaf9a3a3139/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/a04d1bb46ef7/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4420/10201304/44d14ad3a4e0/gr6.jpg

相似文献

1
Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix.口服促性腺激素释放激素拮抗剂艾拉戈利的临床开发
F S Rep. 2023 Feb 4;4(2 Suppl):65-72. doi: 10.1016/j.xfre.2023.02.002. eCollection 2023 Jun.
2
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.子宫肌瘤所致月经过多女性中，elagolix加用反向添加疗法的反应预测因素。
Am J Obstet Gynecol. 2021 Jan;224(1):72.e1-72.e50. doi: 10.1016/j.ajog.2020.07.032. Epub 2020 Jul 20.
3
Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.奥瑞安娜：新药获批用于治疗子宫肌瘤导致的月经过多。
Ann Pharmacother. 2022 Jan;56(1):93-101. doi: 10.1177/10600280211015987. Epub 2021 May 17.
4
Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.艾拉戈利克作为子宫肌瘤女性口服治疗药物的临床应用：关于新出现疗效数据的简短报告
Int J Womens Health. 2019 Oct 22;11:535-546. doi: 10.2147/IJWH.S185023. eCollection 2019.
5
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.Elagolix 治疗子宫肌瘤所致重度月经过多的女性患者。
N Engl J Med. 2020 Jan 23;382(4):328-340. doi: 10.1056/NEJMoa1904351.
6
Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.埃尔戈利克斯联合小剂量雌二醇/醋酸炔诺酮治疗子宫肌瘤患者的群体药代动力学。
Clin Pharmacokinet. 2022 Apr;61(4):577-587. doi: 10.1007/s40262-021-01096-w. Epub 2021 Dec 8.
7
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.艾拉戈利克联合补充治疗对子宫肌瘤合并子宫腺肌病女性的疗效与安全性。
F S Rep. 2021 May 26;2(3):338-346. doi: 10.1016/j.xfre.2021.05.004. eCollection 2021 Sep.
8
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.Elagolix 治疗子宫肌瘤相关重度月经过多的 2a 期概念验证研究结果。
Fertil Steril. 2017 Jul;108(1):152-160.e4. doi: 10.1016/j.fertnstert.2017.05.006. Epub 2017 Jun 1.
9
Elagolix: First Global Approval.依葫芦醇：全球首次批准。
Drugs. 2018 Sep;78(14):1501-1508. doi: 10.1007/s40265-018-0977-4.
10
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.Elagolix 治疗伴有月经过多和子宫肌瘤的女性长达 12 个月。
Obstet Gynecol. 2020 Jun;135(6):1313-1326. doi: 10.1097/AOG.0000000000003869.

引用本文的文献

1
Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.促性腺激素释放激素拮抗剂治疗子宫肌瘤的疗效：一项荟萃分析。
Arch Gynecol Obstet. 2025 Mar;311(3):685-696. doi: 10.1007/s00404-025-07932-9. Epub 2025 Jan 16.
2
The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study.艾拉戈利克在控制性卵巢刺激过程中抑制排卵的作用：一项回顾性队列研究。
F S Rep. 2024 Jul 4;5(4):356-362. doi: 10.1016/j.xfre.2024.06.006. eCollection 2024 Dec.
3
Computational drug repurposing effort for identifying novel hits for the treatment of diseases such as endometriosis, uterine fibroids, and prostate cancer.

本文引用的文献

1
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.Elagolix 治疗伴有月经过多和子宫肌瘤的女性长达 12 个月。
Obstet Gynecol. 2020 Jun;135(6):1313-1326. doi: 10.1097/AOG.0000000000003869.
2
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.Elagolix 治疗子宫肌瘤所致重度月经过多的女性患者。
N Engl J Med. 2020 Jan 23;382(4):328-340. doi: 10.1056/NEJMoa1904351.
3
Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
用于识别治疗子宫内膜异位症、子宫肌瘤和前列腺癌等疾病新靶点的计算药物重新利用研究。
Turk J Chem. 2024 Jan 4;48(2):402-421. doi: 10.55730/1300-0527.3667. eCollection 2024.
4
Abnormal uterine bleeding: The well-known and the hidden face.异常子宫出血：广为人知与隐匿的一面。
J Endometr Uterine Disord. 2024 Jun;6. doi: 10.1016/j.jeud.2024.100071. Epub 2024 Apr 1.
5
Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids.子宫肌瘤可能的靶向治疗和预防的新方法。
Diseases. 2023 Nov 1;11(4):156. doi: 10.3390/diseases11040156.
口服促性腺激素释放激素拮抗剂艾拉戈利克治疗子宫内膜异位症相关疼痛的临床评估
Pain Manag. 2019 Sep;9(5):497-515. doi: 10.2217/pmt-2019-0010. Epub 2019 Aug 22.
4
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.Elagolix 单药治疗或加用激素补充治疗伴有月经过多和子宫肌瘤的女性：一项随机对照试验。
Obstet Gynecol. 2018 Nov;132(5):1252-1264. doi: 10.1097/AOG.0000000000002933.
5
Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain.子宫内膜异位症每日疼痛影响日记项目的开发与验证，用于评估痛经和非经期盆腔疼痛。
Reprod Sci. 2018 Nov;25(11):1567-1576. doi: 10.1177/1933719118789509. Epub 2018 Jul 22.
6
Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.Elagolix 治疗子宫内膜异位症女性的长期结局：两项扩展研究结果。
Obstet Gynecol. 2018 Jul;132(1):147-160. doi: 10.1097/AOG.0000000000002675.
7
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.Elagolix 治疗子宫肌瘤相关重度月经过多的 2a 期概念验证研究结果。
Fertil Steril. 2017 Jul;108(1):152-160.e4. doi: 10.1016/j.fertnstert.2017.05.006. Epub 2017 Jun 1.
8
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.Elagolix，一种口服 GnRH 拮抗剂，治疗子宫内膜异位症相关疼痛。
N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19.
9
Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women.在健康绝经前女性中，艾拉戈利克对促性腺激素和卵巢激素的剂量依赖性抑制作用。
J Clin Endocrinol Metab. 2017 May 1;102(5):1683-1691. doi: 10.1210/jc.2016-3845.
10
Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.R-(+)-4-{2-[5-(2-氟-3-甲氧基苯基)-3-(2-氟-6-[三氟甲基]苄基)-4-甲基-2,6-二氧代-3,6-二氢-2H-嘧啶-1-基]-1-苯乙基氨基}丁酸钠（艾拉戈利）的发现，一种强效且口服可用的人促性腺激素释放激素受体非肽拮抗剂。
J Med Chem. 2008 Dec 11;51(23):7478-85. doi: 10.1021/jm8006454.